Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PDE9A | O76083 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.30 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20417264 | 0.81 | HPGD (0.47) | HPGDALDH1A1MEN1KMT2APOLB | |
| SCHEMBL2739925 | 0.81 | DPP4 (0.41) | DPP4DPP7EPHX2ALDH1A1MEN1 | |
| SCHEMBL30943584 | 0.79 | HPGD (0.50) | DPP4DPP7HPGDALDH1A1MEN1 | |
| SCHEMBL19578176 | 0.76 | SMN1; SMN2 (0.47) | HPGDALDH1A1MEN1KMT2A | |
| SCHEMBL21310237 | 0.74 | DPP4 (0.44) | DPP4DPP7 | |
| SCHEMBL20970568 | 0.73 | HRH3 (0.39) | DPP4DPP7CYP2D6ALDH1A1 | |
| SCHEMBL15203488 | 0.72 | DPP4 (0.43) | DPP4DPP7 | |
| SCHEMBL3434463 | 0.72 | EPHX2 (0.55) | HPGDEPHX2CYP2D6ALDH1A1MEN1 | |
| SCHEMBL27812244 | 0.71 | ALDH1A1 (0.43) | DPP4DPP7HPGDEPHX2ALDH1A1 | |
| SCHEMBL19704613 | 0.71 | HRH3 (0.53) | HPGDEPHX2CYP2D6ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219975-A1 | PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS | BEONE MEDICINES I GMBH (CH) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219975-A1 | PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS | BIRC2, BIRC3, API5 | DPP4 1884/4885DPP7 2007/4885HPGD 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.